181 related articles for article (PubMed ID: 28831243)
1. Autoinjector preference among patients with multiple sclerosis: results from a national survey.
Limmroth V; Reischl J; Mann B; Morosov X; Kokoschka A; Weller I; Schreiner T
Patient Prefer Adherence; 2017; 11():1325-1334. PubMed ID: 28831243
[TBL] [Abstract][Full Text] [Related]
2. Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors.
Barone DA; Singer BA; Merkov L; Rametta M; Suarez G
Neurol Ther; 2016 Dec; 5(2):155-167. PubMed ID: 27277705
[TBL] [Abstract][Full Text] [Related]
3. Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.
Kleiter I; Lang M; Jeske J; Norenberg C; Stollfuß B; Schürks M
BMC Neurol; 2017 Sep; 17(1):174. PubMed ID: 28877664
[TBL] [Abstract][Full Text] [Related]
4. Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).
Ziemssen T; Sylvester L; Rametta M; Ross AP
Neurol Ther; 2015 Dec; 4(2):125-36. PubMed ID: 26662362
[TBL] [Abstract][Full Text] [Related]
5. Autoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviPro™ 30G and Betacomfort
Thakur K; Manuel L; Tomlinson M
Pragmat Obs Res; 2013; 4():19-26. PubMed ID: 27774021
[TBL] [Abstract][Full Text] [Related]
6. Preferences and Perspectives of Specialist Multiple Sclerosis Nurses and Patients with Multiple Sclerosis Regarding the New RebiSmart
Colten SS; di Cantogno EV; Jack D
Med Devices (Auckl); 2024; 17():59-71. PubMed ID: 38404632
[TBL] [Abstract][Full Text] [Related]
7. Evolution of the RebiSmart
Lin YT; Will T; Wickham C; Boeree P; Jack D; Keiser M
Patient Prefer Adherence; 2023; 17():1923-1933. PubMed ID: 37581193
[TBL] [Abstract][Full Text] [Related]
8. Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years.
Piras F; Arnaud L; Henninger E; Keiser M; Seitzinger A; Jack D; Le Masne Q
Expert Opin Drug Deliv; 2023 Jun; 20(6):863-870. PubMed ID: 37273189
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT
Köhler W; Bayer-Gersmann K; Neußer T; Schürks M; Ziemssen T
Front Neurol; 2021; 12():643126. PubMed ID: 33716945
[No Abstract] [Full Text] [Related]
10. BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT
Patti F; Martínez Ginés ML; Norenberg C; Duarte Caron F
Patient Prefer Adherence; 2020; 14():771-779. PubMed ID: 32425509
[TBL] [Abstract][Full Text] [Related]
11. Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b.
Weller I; Saake A; Schreiner T; Vogelreuter J; Petroff N
Patient Prefer Adherence; 2015; 9():951-9. PubMed ID: 26185425
[TBL] [Abstract][Full Text] [Related]
12. A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector.
Farej R; Rametta M; La Rose A; Quillen A; McLeod K
Neurol Ther; 2022 Mar; 11(1):373-384. PubMed ID: 35064907
[TBL] [Abstract][Full Text] [Related]
13. Real-World Assessment of Interferon-β-1b and Interferon-β-1a Adherence Before and After the Introduction of the BETACONNECT
Butler O; Heeg S; Holl K; Frenz AK; Wicklein EM; Rametta M; Yeo S
Drugs Real World Outcomes; 2021 Sep; 8(3):359-367. PubMed ID: 33928518
[TBL] [Abstract][Full Text] [Related]
14. The BETACONNECT™ system: MS therapy goes digital.
Limmroth V; Bartzokis I; Bonmann E; Kusel P; Schreiner T; Schürks M
Neurodegener Dis Manag; 2018 Dec; 8(6):399-410. PubMed ID: 30278827
[TBL] [Abstract][Full Text] [Related]
15. Patients' and nurses' preferences for autoinjectors for rheumatoid arthritis: results of a European survey.
Tischer B; Mehl A
Patient Prefer Adherence; 2018; 12():1413-1424. PubMed ID: 30122906
[TBL] [Abstract][Full Text] [Related]
16. Autoinjector preference in multiple sclerosis and the role of nurses in treatment decisions: results from an international survey in Europe and the USA.
Verdun di Cantogno E; Tomlinson M; Manuel L; Thakur K
Pragmat Obs Res; 2014; 5():53-64. PubMed ID: 27774029
[TBL] [Abstract][Full Text] [Related]
17. Patients' Perceptions and Preferences Regarding Two Different Forms of Methotrexate Autoinjectors for Moderate to Severe Rheumatoid Arthritis: A European Crossover Survey.
Zeitoun JD; Morvan Y
Patient Prefer Adherence; 2020; 14():2177-2185. PubMed ID: 33177812
[TBL] [Abstract][Full Text] [Related]
18. Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study.
Zecca C; Disanto G; Mühl S; Gobbi C
BMC Neurol; 2017 Sep; 17(1):171. PubMed ID: 28870152
[TBL] [Abstract][Full Text] [Related]
19. Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe.
Thakur K; Biberger A; Handrich A; Rezk MF
Rheumatol Ther; 2016 Dec; 3(2):245-256. PubMed ID: 27817152
[TBL] [Abstract][Full Text] [Related]
20. Nurse and Patient Perceptions and Preferences for Subcutaneous Autoinjectors for Inflammatory Joint or Bowel Disease: Findings from a European Survey.
Fenwick S; Thakur K; Munro D
Rheumatol Ther; 2019 Jun; 6(2):195-206. PubMed ID: 30790242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
